BofA analyst Joanna Gajuk raised the firm’s price target on HCA Healthcare (HCA) to $430 from $375 and keeps a Neutral rating on the shares. While hospital fundamentals should remain solid in the second half, the firm is concerned that the policy and reimbursement environment will be more negative compared to recent years, says the analyst, who prefers post-acute over hospitals as the least exposed to the upcoming cuts given this backdrop. The firm is updating estimates and price targets for several companies in its health care facilities coverage.
Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on HCA:
- HCA Healthcare price target raised to $417 from $404 at Bernstein
- Balanced Outlook on HCA Healthcare: Strong Margins Amid Slower Growth and Policy Risks
- HCA Healthcare price target raised to $423 from $380 at Baird
- HCA Healthcare’s Earnings Call: Strong Growth Amid Challenges
- HCA Healthcare price target lowered to $400 from $410 at Morgan Stanley